Annual report pursuant to Section 13 and 15(d)

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details)

v3.20.1
Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Antidilutive securities excluded from computation of diluted weighted shares outstanding 24,364,595 22,899,321
Stock Options and Unvested Restricted Stock Awards [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 5,903,529 3,327,140
Unit Purchase Options - "UPO-Z" /"UPO-W" - as to Shares of common stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding [1] 53,000 53,000
Unit Purchase Options - "UPO-Z" - as to Shares Underlying Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding [1] 53,000 53,000
Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 16,815,039 16,815,039
Series W Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 381,818 381,818
Series S Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding [2] 1,199,383
Series B Convertible Preferred Stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding [3] 1,158,209 1,069,941
[1] On August 22, 2018, the "UPO Exchange Offer" was completed, wherein, 53,000 "UPO-Z" were issued-upon-exchange of all the previously issued and outstanding 53,000 UPO-W. The UPO-Z may be exercised to purchase a unit comprised of one share of common stock of the Company and one Series Z Warrant; and the UPO-W was exercisable to purchase a unit comprised of one share of common stock of the Company and one Series W Warrant. See Note 14, Stockholders' Equity and Common Stock Purchase Warrants, for a discussion of the UPO-Z, UPO-W, and the August 22, 2018 UPO Exchange Offer.
[2] The Series S Warrants were issued in connection with the Note and Security Purchase Agreement with Scopia Holdings LLC. The Series S Warrants were not included in weighted average shares outstanding for the year ended December 31, 2018 due to certain contractual restrictions on the ability of the holder to exercise the Series S Warrant, with such contractual restrictions ending in January 2019.
[3] If converted at the election of the holder, the shares of Series B Convertible Preferred Stock issued and outstanding would result in a corresponding number of additional outstanding shares of common stock of the Company.